LivaNova (NASDAQ:LIVN) Releases Quarterly Earnings Results, Beats Expectations By $0.17 EPS

LivaNova (NASDAQ:LIVN) posted its quarterly earnings data on Wednesday. The company reported $1.26 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.17, FiscalAI reports. LivaNova had a net margin of 7.48% and a return on equity of 16.48%. The firm had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. During the same period last year, the firm posted $1.05 EPS. LivaNova’s quarterly revenue was up 10.8% on a year-over-year basis. LivaNova updated its FY 2026 guidance to 4.300-4.400 EPS.

Here are the key takeaways from LivaNova’s conference call:

• Q2 revenue rose 9.8% on a constant-currency basis to a record $391 million, while adjusted EPS increased to $1.26 from $1.05, supported by growth in Cardiopulmonary and Epilepsy.
• LivaNova raised its 2026 revenue-growth outlook to 8%–9% and adjusted EPS guidance to $4.30–$4.40; Cardiopulmonary and Epilepsy growth expectations were also increased.
• The company is expanding oxygenator capacity through a new production line expected to go live in the second half of 2026 and a long-term Thermo Fisher agreement for a critical component, supporting potential market-share gains.
• Epilepsy momentum benefited from improved reimbursement, clinical evidence, higher realized pricing and a stronger patient funnel; management said new-patient implants are growing in existing accounts and through new account activations.
• Adjusted free-cash-flow guidance was reduced to $140 million–$160 million from $160 million–$180 million as capital spending rises to $135 million, while the OSA PMA supplement submission was pushed to between the second half of 2026 and the first half of 2027.

LivaNova Trading Down 8.4%

NASDAQ:LIVN traded down $7.18 during trading hours on Wednesday, reaching $78.14. 1,862,507 shares of the company were exchanged, compared to its average volume of 605,780. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of 40.07 and a beta of 0.86. The stock has a 50 day simple moving average of $79.54 and a 200 day simple moving average of $70.61. LivaNova has a 52-week low of $45.64 and a 52-week high of $85.76. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.33 and a quick ratio of 1.11.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. KeyCorp increased their price target on shares of LivaNova from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Monday, June 22nd. Freedom Capital raised LivaNova to a “hold” rating in a research note on Tuesday, June 30th. Mizuho raised their price objective on LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th. Stifel Nicolaus set a $85.00 target price on LivaNova in a report on Wednesday. Finally, Robert W. Baird lowered their price objective on shares of LivaNova from $78.00 to $76.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $83.50.

Key Headlines Impacting LivaNova

Here are the key news stories impacting LivaNova this week:

• Positive Sentiment: Quarterly results exceeded expectations: LivaNova reported second-quarter earnings of $1.26 per share, versus the $1.08–$1.09 analyst consensus, while revenue rose 10.8% year over year to $390.6 million, above the approximately $380.5 million estimate. LivaNova Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: 2026 earnings guidance was raised: The company now expects full-year adjusted EPS of $4.30 to $4.40, above the $4.15 consensus estimate. Revenue guidance was approximately $1.5 billion, broadly in line with expectations. LivaNova exceeds second-quarter forecasts and increases 2026 outlook
• Positive Sentiment: Analyst became more bullish: Needham raised its price target from $81 to $93 and assigned a Buy rating, implying meaningful potential upside from the referenced trading level. Benzinga
• Neutral Sentiment: Momentum has been strong: LivaNova recently reached a fresh 52-week high, but commentary noted that investors must weigh the company’s improving fundamentals against the possibility that additional gains are already reflected in the valuation. LivaNova Hits Fresh High
• Negative Sentiment: Shares pulled back despite the beats: The decline following the earnings release may reflect profit-taking after the recent rally, or investor concern that the roughly 40 times earnings valuation leaves limited room for further upside unless growth accelerates.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,800 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $75.75, for a total value of $136,350.00. Following the transaction, the director directly owned 7,228 shares of the company’s stock, valued at approximately $547,521. This trade represents a 19.94% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.35% of the stock is currently owned by insiders.

Institutional Investors Weigh In On LivaNova

A number of institutional investors have recently added to or reduced their stakes in LIVN. State of Wyoming acquired a new stake in LivaNova during the second quarter worth about $31,000. EverSource Wealth Advisors LLC increased its position in LivaNova by 998.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 703 shares of the company’s stock worth $32,000 after purchasing an additional 639 shares in the last quarter. Quarry LP purchased a new position in LivaNova in the third quarter valued at approximately $36,000. UMB Bank n.a. raised its holdings in LivaNova by 22.6% in the fourth quarter. UMB Bank n.a. now owns 971 shares of the company’s stock valued at $60,000 after buying an additional 179 shares during the period. Finally, Johnson Financial Group Inc. acquired a new position in LivaNova during the third quarter valued at approximately $63,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.